2025-523010-89-00招募中1 期
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)
35Pharma Inc.1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2025年12月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 2
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
George Georges
Scientific
35Pharma Inc.
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapyPeritoneal carcinomatosis (PC) from colorectal carcinoma2024-511853-23-00Oncoinvent ASA54
已完成
1 期
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy ParticipantsRespiratory syncytial virus infection2022-502926-42-00Merck Sharp & Dohme LLC32
招募中
1 期
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)Chronic hepatitis B infection2023-508444-22-01Region Midtjylland30
已完成
1 期
MK-7480 Multiple Ascending Dose Study in Healthy ParticipantsNon-alcoholic steatohepatitis2023-508982-34-00Merck Sharp & Dohme LLC44
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donorsPatients with hematological malignancies (Cf. inclusion criteria) HLA-DPB1*04:01 positive allografted with a geno- or pheno- or haplo-identical donor or cord blood HLA-DPB1*04:01 negative2024-515504-39-00Centre Hospitalier Universitaire De Nantes6